Last reviewed · How we verify
Arm 5- Tirzepatide
GLP-1 receptor agonist
GLP-1 receptor agonist Used for Type 2 diabetes, Obesity.
At a glance
| Generic name | Arm 5- Tirzepatide |
|---|---|
| Sponsor | Lexaria Bioscience Corp. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 1 |
Mechanism of action
Tirzepatide activates the GLP-1 receptor, mimicking the action of the incretin hormone glucagon-like peptide-1 (GLP-1) to regulate blood sugar levels.
Approved indications
- Type 2 diabetes
- Obesity
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) (PHASE3)
- GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial (PHASE2, PHASE3)
- Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity (PHASE2)
- Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial (PHASE2)
- GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes (PHASE3)
- Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer (PHASE2)
- Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer (PHASE2)
- Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm 5- Tirzepatide CI brief — competitive landscape report
- Arm 5- Tirzepatide updates RSS · CI watch RSS
- Lexaria Bioscience Corp. portfolio CI